|
|
Volumn 361, Issue 25, 2009, Pages 2485-2487
|
|
Treatment of lung cancer [1]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOPLATIN;
GEFITINIB;
PACLITAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
PROTEIN TYROSINE KINASE INHIBITOR;
ANTINEOPLASTIC AGENT;
QUINAZOLINE DERIVATIVE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER THERAPY;
LETTER;
LUNG CANCER;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
TREATMENT DURATION;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
COMPARATIVE STUDY;
GENE MUTATION;
HUMAN;
PHARMACOGENETICS;
PREDICTION;
TREATMENT OUTCOME;
DISEASE FREE SURVIVAL;
GENETICS;
LUNG TUMOR;
MORTALITY;
MUTATION;
NOTE;
SURVIVAL RATE;
DRUG ANTAGONISM;
PROPORTIONAL HAZARDS MODEL;
SURVIVAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARBOPLATIN;
DISEASE-FREE SURVIVAL;
HUMANS;
LUNG NEOPLASMS;
MUTATION;
PACLITAXEL;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SURVIVAL RATE;
PROPORTIONAL HAZARDS MODELS;
SURVIVAL ANALYSIS;
|
|
EID: 72449197970
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc0909634 Document Type: Letter |
|
Times cited : (8)
|
|
References (1)
|
